Johnson & Johnson Price to Sales Ratio 2010-2024 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of April 11, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2025-04-11 |
151.73 |
|
4.15 |
| 2024-12-31 |
143.47 |
$36.59 |
3.92 |
| 2024-09-30 |
159.49 |
$35.68 |
4.47 |
| 2024-06-30 |
142.76 |
$34.80 |
4.10 |
| 2024-03-31 |
153.27 |
$33.72 |
4.54 |
| 2023-12-31 |
150.72 |
$32.94 |
4.58 |
| 2023-09-30 |
148.58 |
$29.30 |
5.07 |
| 2023-06-30 |
156.76 |
$28.44 |
5.51 |
| 2023-03-31 |
145.70 |
$29.25 |
4.98 |
| 2022-12-31 |
164.87 |
$30.01 |
5.49 |
| 2022-09-30 |
151.49 |
$28.96 |
5.23 |
| 2022-06-30 |
163.51 |
$30.17 |
5.42 |
| 2022-03-31 |
162.21 |
$29.89 |
5.43 |
| 2021-12-31 |
155.57 |
$29.46 |
5.28 |
| 2021-09-30 |
145.91 |
$34.22 |
4.26 |
| 2021-06-30 |
147.96 |
$33.39 |
4.43 |
| 2021-03-31 |
146.70 |
$31.54 |
4.65 |
| 2020-12-31 |
139.60 |
$30.94 |
4.51 |
| 2020-09-30 |
131.15 |
$30.25 |
4.34 |
| 2020-06-30 |
123.07 |
$30.12 |
4.09 |
| 2020-03-31 |
113.96 |
$30.88 |
3.69 |
| 2019-12-31 |
125.97 |
$30.55 |
4.12 |
| 2019-09-30 |
110.96 |
$30.30 |
3.66 |
| 2019-06-30 |
118.56 |
$29.99 |
3.95 |
| 2019-03-31 |
118.19 |
$30.01 |
3.94 |
| 2018-12-31 |
108.39 |
$29.91 |
3.62 |
| 2018-09-30 |
115.31 |
$29.79 |
3.87 |
| 2018-06-30 |
100.60 |
$29.51 |
3.41 |
| 2018-03-31 |
105.46 |
$28.73 |
3.67 |
| 2017-12-31 |
114.25 |
$27.86 |
4.10 |
| 2017-09-30 |
105.66 |
$26.99 |
3.91 |
| 2017-06-30 |
106.84 |
$26.21 |
4.08 |
| 2017-03-31 |
99.92 |
$25.95 |
3.85 |
| 2016-12-31 |
91.82 |
$25.74 |
3.57 |
| 2016-09-30 |
93.50 |
$25.58 |
3.66 |
| 2016-06-30 |
95.38 |
$25.27 |
3.77 |
| 2016-03-31 |
84.47 |
$24.98 |
3.38 |
| 2015-12-31 |
79.62 |
$24.90 |
3.20 |
| 2015-09-30 |
71.83 |
$24.94 |
2.88 |
| 2015-06-30 |
74.42 |
$25.29 |
2.94 |
| 2015-03-31 |
76.26 |
$25.75 |
2.96 |
| 2014-12-31 |
78.72 |
$25.91 |
3.04 |
| 2014-09-30 |
79.72 |
$25.91 |
3.08 |
| 2014-06-30 |
77.72 |
$25.56 |
3.04 |
| 2014-03-31 |
72.47 |
$24.96 |
2.90 |
| 2013-12-31 |
67.09 |
$24.78 |
2.71 |
| 2013-09-30 |
63.06 |
$24.65 |
2.56 |
| 2013-06-30 |
61.99 |
$24.60 |
2.52 |
| 2013-03-31 |
58.42 |
$24.30 |
2.40 |
| 2012-12-31 |
49.83 |
$24.00 |
2.08 |
| 2012-09-30 |
48.56 |
$23.61 |
2.06 |
| 2012-06-30 |
47.18 |
$23.32 |
2.02 |
| 2012-03-31 |
45.62 |
$23.40 |
1.95 |
| 2011-12-31 |
44.96 |
$23.42 |
1.92 |
| 2011-09-30 |
43.26 |
$23.17 |
1.87 |
| 2011-06-30 |
44.78 |
$22.79 |
1.97 |
| 2011-03-31 |
39.55 |
$22.30 |
1.77 |
| 2010-12-31 |
40.91 |
$22.06 |
1.85 |
| 2010-09-30 |
40.63 |
$22.38 |
1.82 |
| 2010-06-30 |
38.37 |
$22.40 |
1.71 |
| 2010-03-31 |
41.98 |
$22.40 |
1.87 |
| 2009-12-31 |
41.15 |
$22.20 |
1.85 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$394.223B |
$88.821B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
